SCATTOLIN, DANIELA
 Distribuzione geografica
Continente #
AS - Asia 1.091
NA - Nord America 899
EU - Europa 496
SA - Sud America 124
AF - Africa 119
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 8
Totale 2.748
Nazione #
US - Stati Uniti d'America 828
SG - Singapore 282
VN - Vietnam 276
CN - Cina 205
IT - Italia 200
HK - Hong Kong 88
BR - Brasile 82
FR - Francia 38
IN - India 37
GB - Regno Unito 32
BD - Bangladesh 29
DE - Germania 26
NL - Olanda 23
PL - Polonia 22
SE - Svezia 20
FI - Finlandia 16
TR - Turchia 15
RU - Federazione Russa 14
IQ - Iraq 13
SA - Arabia Saudita 12
CA - Canada 11
JO - Giordania 11
ID - Indonesia 10
PH - Filippine 10
KR - Corea 9
ZA - Sudafrica 9
IE - Irlanda 8
JP - Giappone 8
MX - Messico 8
RS - Serbia 8
XK - ???statistics.table.value.countryCode.XK??? 8
AE - Emirati Arabi Uniti 7
AR - Argentina 7
AT - Austria 7
CO - Colombia 7
PK - Pakistan 7
AU - Australia 6
AZ - Azerbaigian 6
CM - Camerun 6
ES - Italia 6
PE - Perù 6
TN - Tunisia 6
AL - Albania 5
AO - Angola 5
BJ - Benin 5
CL - Cile 5
CR - Costa Rica 5
DK - Danimarca 5
GE - Georgia 5
IL - Israele 5
JM - Giamaica 5
LB - Libano 5
LC - Santa Lucia 5
LV - Lettonia 5
LY - Libia 5
PT - Portogallo 5
BE - Belgio 4
DO - Repubblica Dominicana 4
GH - Ghana 4
GN - Guinea 4
GR - Grecia 4
HR - Croazia 4
HU - Ungheria 4
KE - Kenya 4
KH - Cambogia 4
LA - Repubblica Popolare Democratica del Laos 4
MA - Marocco 4
MN - Mongolia 4
MW - Malawi 4
NA - Namibia 4
NP - Nepal 4
PR - Porto Rico 4
PY - Paraguay 4
SD - Sudan 4
SI - Slovenia 4
TL - Timor Orientale 4
TT - Trinidad e Tobago 4
TW - Taiwan 4
UA - Ucraina 4
VE - Venezuela 4
AF - Afghanistan, Repubblica islamica di 3
BA - Bosnia-Erzegovina 3
BO - Bolivia 3
BS - Bahamas 3
BW - Botswana 3
BZ - Belize 3
CH - Svizzera 3
CI - Costa d'Avorio 3
CZ - Repubblica Ceca 3
DZ - Algeria 3
EC - Ecuador 3
EE - Estonia 3
ET - Etiopia 3
HT - Haiti 3
MD - Moldavia 3
ME - Montenegro 3
MG - Madagascar 3
MY - Malesia 3
NG - Nigeria 3
PA - Panama 3
Totale 2.655
Città #
Singapore 154
Ashburn 145
San Jose 123
Hong Kong 76
Hanoi 73
Ho Chi Minh City 70
Fairfield 52
Chandler 45
Beijing 36
Santa Clara 33
Los Angeles 31
Padova 25
Da Nang 23
Milan 23
Houston 21
New York 21
Cambridge 17
São Paulo 16
Lauterbourg 15
Woodbridge 15
London 14
Padua 14
Chicago 13
Seattle 13
Boardman 12
Haiphong 12
Amman 11
Council Bluffs 10
Helsinki 10
San Diego 10
Warsaw 10
Bytom 9
Orem 9
Buffalo 8
Hefei 8
Arezzo 7
Montreal 7
Munich 7
Wilmington 7
Ann Arbor 6
Biên Hòa 6
Guangzhou 6
Istanbul 6
Medford 6
Naples 6
Princeton 6
Rome 6
Amsterdam 5
Ankara 5
Baku 5
Bologna 5
Castries 5
Chennai 5
Cotonou 5
Des Moines 5
Dublin 5
Frankfurt am Main 5
Luanda 5
Belgrade 4
Bến Tre 4
Columbus 4
Conakry 4
Copenhagen 4
Dallas 4
Dammam 4
Denver 4
Dili 4
Hsinchu County 4
Johannesburg 4
Lahore 4
Lima 4
Ludhiana 4
Nairobi 4
Nha Trang 4
Phoenix 4
Pristina 4
Riga 4
Riyadh 4
Seoul 4
Shanghai 4
Tokyo 4
Tân Tiến 4
Tây Ninh 4
Vientiane 4
Abidjan 3
Accra 3
Antananarivo 3
Asunción 3
Athens 3
Baghdad 3
Belo Horizonte 3
Bogotá 3
Boston 3
Brescia 3
Bắc Ninh 3
Can Tho 3
Castrezzato 3
Cebu City 3
Dar es Salaam 3
Douala 3
Totale 1.460
Nome #
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study 282
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non–small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy 257
149P First-line (1L) osimertinib in EGFR mutant (mut) advanced non-small cell lung cancer (aNSCLC) patients (pts): Progression (PD) pattern and safety in the real-world (RW) 245
Clinical features and progression pattern of T790M+ compared with T790M-EGFR mutant NSCLC 243
Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines 229
Baseline levels and dynamic changes of cfDNA, tumor fraction and mutations to anticipate the clinical course of small cell lung cancer (SCLC) patients treated with first-line atezolizumab and chemotherapy: an hypothesis generating study (CATS/ML43257) 218
Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World 197
NGS detection of gene rearrangements and METexon14 mutations in liquid biopsy of advanced NSCLC patients: A study of two Italian centers 194
Secondary prevention and treatment innovation of early stage non-small cell lung cancer: Impact on diagnostic-therapeutic pathway from a multidisciplinary perspective 187
1398P Real-life progression (PD) pattern of EGFR mutant advanced non-small cell lung cancer (aNSCLC) patients (pts) receiving systemic therapy after first- or second-generation tyrosine kinase inhibitor (1-2 gen TKI) 187
The emerging role of Schlafen-11 (SLFN11) in predicting response to anticancer treatments: Focus on small cell lung cancer 151
Small bowel edema and lymphocytic duodenitis as severe reversible gastrointestinal toxicity of selpercatinib in RET fusion–positive non–small cell lung cancer: a case report 123
Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database 83
Circulating microRNAs as biomarkers for risk assessment and prognostic stratification of pleural mesothelioma 77
Clinical insight on the pathway of SLFN11 as emergent biomarker in SCLC 42
Outcome and safety of lurbinectedin as compassionate use in extensive stage small cell lung cancer: A multicentric international cohort 41
Dissecting the prognostic role of metabolic markers in lung neuroendocrine Tumors: The MONET study 17
Totale 2.773
Categoria #
all - tutte 7.317
article - articoli 7.317
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.634


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202111 0 0 0 0 0 0 0 0 0 0 0 11
2021/2022171 3 16 34 6 10 31 25 4 6 7 8 21
2022/2023102 12 16 5 13 8 8 1 10 21 4 4 0
2023/2024128 13 11 13 20 7 18 11 3 3 13 14 2
2024/2025407 2 26 20 14 53 10 22 39 35 16 68 102
2025/20261.926 97 109 206 244 159 69 409 148 235 145 103 2
Totale 2.773